Stockpolly
Search
ELDN · NASDAQ · Biotechnology

Eledon Pharmaceuticals (ELDN)

Develops tegoprubart for transplant rejection and CD40L-linked immune disease.

$3.15
Pre-market+0.16 (+5.53%)
At close$2.99(−0.83%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
111011152125182519212123
Research & development877101718142015171718
333447444445
General & administrative333447444445
Operating income−11−10−11−15−21−25−18−25−19−21−21−23
11−13−3097−191114211−18−9
Interest expense000000000000
Other non-operating income0−11330−9719−11−14−2−1118−9
Income before tax−10−10−24−4577−44−6−11−17−10−39−32
Income tax expense000000000000
Net income from continuing operations−10−10−24−4577−45−6−11−17−10−39−32
Net income−10−10−24−4577−45−6−11−17−10−39−32
EPS, basic−$0.33−$3.55−$0.79−$1.06$1.05−$0.75−$0.08−$0.15−$0.23−$0.14−$0.35−$0.27
EPS, diluted−$0.33−$3.55−$0.79−$1.06−$0.32−$0.75−$0.08−$0.15−$0.23−$0.14−$0.35−$0.27
Weighted average shares, basic30243042526077777775112114
Weighted average shares, diluted30243042556077777775112114
EBITDA−11−9−24−4577−44−6−11−17−10−39−14
Depreciation & amortization000000000000
EBIT−11−9−24−4577−44−6−11−17−10−39−14